Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
C 35.65 -1.25% -0.45
ZYME closed down 1.25 percent on Friday, September 17, 2021, on 1.96 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ZYME trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish -1.25%
MACD Bullish Centerline Cross Bullish -1.25%
Pocket Pivot Bullish Swing Setup -1.25%
Volume Surge Other -1.25%
Upper Bollinger Band Walk Strength -1.25%
BB Squeeze Ended Range Expansion -1.25%
Older End-of-Day Signals for ZYME ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 1 day ago
Up 3% 1 day ago
Up 2% 1 day ago
5x Volume Pace 1 day ago
2x Volume Pace 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zymeworks Inc. Description

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Immune System Cancers Cancer Immunotherapy Monoclonal Antibodies Antibody Her2 Sutro Biopharma Toxins Glycoproteins Biological Systems Bispecific Monoclonal Antibody Protein Engineering

Is ZYME a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.03
52 Week Low 24.82
Average Volume 406,783
200-Day Moving Average 37.11
50-Day Moving Average 33.53
20-Day Moving Average 32.96
10-Day Moving Average 33.21
Average True Range 1.68
ADX 16.11
+DI 26.99
-DI 13.83
Chandelier Exit (Long, 3 ATRs) 32.16
Chandelier Exit (Short, 3 ATRs) 35.37
Upper Bollinger Bands 35.18
Lower Bollinger Band 30.73
Percent B (%b) 1.11
BandWidth 13.50
MACD Line 0.35
MACD Signal Line -0.06
MACD Histogram 0.409
Fundamentals Value
Market Cap 1.63 Billion
Num Shares 45.6 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -21.87
Price-to-Sales 105.44
Price-to-Book 5.79
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.80
Resistance 3 (R3) 38.96 38.08 38.28
Resistance 2 (R2) 38.08 37.27 38.00 38.10
Resistance 1 (R1) 36.86 36.78 36.42 36.70 37.92
Pivot Point 35.98 35.98 35.76 35.90 35.98
Support 1 (S1) 34.76 35.17 34.32 34.60 33.38
Support 2 (S2) 33.88 34.68 33.80 33.20
Support 3 (S3) 32.66 33.88 33.03
Support 4 (S4) 32.50